Venture Capital for German Biotech Firms Plummeted in 2025
6 Articles
6 Articles
Biotech companies in Germany often find it difficult to obtain large amounts of investors. As a result, innovations move abroad. This has consequences for the location.
Biotech companies in Germany often find it difficult to obtain large amounts of investors. As a result, innovations move abroad. This has consequences for the location.
Venture capital for German biotech firms plummeted in 2025
BERLIN. Biotech companies in Germany collected significantly less money last year. In the midst of the weak economy, they received around 1.8 billion euros from investors in 2025 and from capital raised on the stock exchange, five percent less than in the previous year. Venture capital investments, with which investors participate in emerging companies, even broke by a third to 601 million [...]
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium


